Abstract: Provided are methods for the isolation of phorbol from seed sources and the use of the phorbol for the generation of tigliane tiglate and derivatives thereof.

Abstract: A system and structure determines when or if a utility cart is entering a restricted geographical area, and can disrupt the ignition of the cart to prevent or at least stop such use. The system can also determine a safe time and location for such ignition disruption. A monitoring device can remotely and reliably monitor the state of charge of the cart's battery, even for carts of a range of different battery energy capacities, rated voltage, and technical makeup, and communicate such information to a computer system. A standalone device can be retrofitted onto an existing golf cart without requiring fundamental changes to the cart's initial construction. The device can include an inexpensive module that can reliably monitor the battery state and implement ignition cutoff without requiring software processing capacity within the module.

Abstract: The disclosure provides methods for determining liver fibrosis development, risk and prognosis.

Abstract: A system and structure determines when or if a utility cart is entering a restricted geographical area, and can disrupt the ignition of the cart to prevent or at least stop such use. The system can also determine a safe time and location for such ignition disruption. A monitoring device can remotely and reliably monitor the state of charge of the cart's battery, even for carts of a range of different battery energy capacities, rated voltage, and technical makeup, and communicate such information to a computer system. A standalone device can be retrofitted onto an existing golf cart without requiring fundamental changes to the cart's initial construction. The device can include an inexpensive module that can reliably monitor the battery state and implement ignition cutoff without requiring software processing capacity within the module.

Abstract: A smokeable material for inclusion in a smoking article, the material comprising particles or fragments comprising acacia gum, wherein the particles or fragments do not comprise a diluent, flavourant or aerosol generating material; and substantially comprise or consist of acacia gum.

Abstract: A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.

Abstract: The disclosure relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.

Abstract: The present disclosure relates to pharmaceutical compositions comprising N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide and a polymer, dosage forms comprising the formulation and methods of treating subjects having cancer.

Abstract: The present disclosure relates to pharmaceutical compositions comprising N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide and a polymer, dosage forms comprising the formulation and methods of treating subjects having cancer.

Abstract: The disclosure relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.

Abstract: A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

Abstract: The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.

Abstract: A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

Abstract: There is provided a solid aerosol generating material including about 5-35 wt % tobacco extract; about 50-80 wt % filler; about 10-35 wt % aerosol generating agent; and about 2.5-10 wt % binder; wherein weight percentage is calculated on a dry weight basis.

Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.

Abstract: The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.

Abstract: A method of producing a smoking article is disclosed. The smoking article comprises a smoke constituent reducing technology which is capable of reducing the concentration of a smoke constituent generated by a smoking article in use. The method comprises in a first step, determining one or more first lateral regions at which, when the smoking article is in use, the smoke constituent is present at a first concentration, and one or more second lateral regions at which, when the smoking article is in use, the smoke constituent is present at a second concentration which is lower than the first concentration. In a second step, the method comprises producing a smoking article in which the smoke constituent reducing technology is targeted to reduce the concentration of the smoke constituent present at the one or more first lateral regions.

Abstract: The present invention relates to a cellulosic material having one or more smoke diluents within its cellular structure and, optionally, one or more smoke diluents on its surface.

Abstract: Methods and compounds useful for inhibiting a phoshpolipase A2 are provided, the methods comprising contacting the phoshpolipase A2 with a compound having the structure A, or pharmaceutically acceptable salts thereof: wherein R1 is H, F, NH2, or COOH; R2 is, H, linear saturated or unsaturated alkyl, alkenyl, or alkynyl; each of R3 and R4 is independently H, linear saturated or unsaturated alkyl, alkenyl, alkynyl, phenyl, or substituted phenyl; R5 is H, (C1-C6) alkyl such as methyl or ethyl; X is aryl or substituted aryl, such as phenyl or a substituted phenyl; and Y is O or S.